Cibus (NASDAQ:CBUS) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Cibus (NASDAQ:CBUS) announced its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.09), FiscalAI reports. The firm had revenue of $0.80 million during the quarter, compared to analyst estimates of $1.30 million. Cibus had a negative net margin of 2,258.89% and a negative return on equity of 287.03%.

Here are the key takeaways from Cibus’ conference call:

• Bio-fragrance opportunity expanded under a direct-sales model: Cibus estimates up to $100 million in peak annual revenue across eight ingredients, with projected gross margins of roughly 50%–70% and no expected manufacturing CapEx. Its first two ingredients are approved for the partner’s products and scale-up has begun, but revenue still depends on formulation success and purchase orders.
• Rice traits advanced toward customer testing and commercialization: Initial Latin American trials showed positive performance, and Interoc has planted Cibus-edited varieties in Ecuador, with results expected in the first quarter of 2027. Cibus targets a Latin American launch as early as 2028, though timing depends on trial results and commercialization planning.
• Near-term financing remains a significant risk: Cibus had $10.7 million in cash at quarter-end and expects it to fund planned expenses only into early Q1 2027; management said additional capital will be needed in the near term. The company reported a $21.9 million quarterly net loss.
• Spending discipline improved, while partner-funded programs progressed: Nine-month operating cash use fell about 19% year over year, and quarterly operating expenses declined roughly $2.7 million. Work began on partner-funded Indian mustard traits, while the U.K. light leaf spot program remained on schedule and pod-shatter material received approval for trial planting in England.

Cibus Price Performance

CBUS traded down $0.07 during trading on Thursday, reaching $1.09. The company had a trading volume of 167,542 shares, compared to its average volume of 353,615. The company has a market cap of $83.31 million, a P/E ratio of -0.66 and a beta of 1.65. Cibus has a 12 month low of $1.07 and a 12 month high of $4.19. The business’s fifty day moving average price is $1.45 and its 200 day moving average price is $1.83.

Analysts Set New Price Targets

CBUS has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a report on Friday, September 25th. Wall Street Zen downgraded Cibus from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.00.

About Cibus

Cibus, Inc. (NASDAQ: CBUS) is an agricultural biotechnology company focused on developing gene-edited crop traits. Its technology is designed to improve the performance, resilience and sustainability of important crops by making targeted changes to plant genetics without introducing foreign DNA. The company’s proprietary Rapid Trait Development System (RTDS) supports the development of traits for crops including canola, rice, soybeans and wheat. Cibus has pursued applications such as herbicide tolerance, pod-shatter reduction and resistance to diseases and other environmental stresses, with the goal of helping growers improve yields, reduce crop losses and use agricultural inputs more efficiently.